LEU is found in 110252 entries

LEU in polymers: 110177 entries. Examples include: 101M, 102L, 102M

LEU as free ligands, exist in 75 entries. Examples include 1A16, 1ABW, 1DGI

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Identifiers L-leucine
(2S)-2-amino-4-methyl-pentanoic acid
Formula C6 H13 N O2
Molecular Weight 131.17 g/mol
Type L-peptide linking
Isomeric SMILES CC(C)C[C@H](N)C(O)=O
InChI InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1

Chemical Details

Formal Charge 0
Atom Count 22
Chiral Atom Count 1
Chiral Atoms CA
Bond Count 21
Aromatic Bond Count 0
Leaving Atoms OXT H2 HXT

Drug Info: DrugBank

DrugBank ID DB00149   (Stereoisomeric match)
Name L-Leucine
  • approved
  • nutraceutical
Description An essential branched-chain amino acid important for hemoglobin formation. [PubChem]
  • (2S)-2-Amino-4-methylpentanoic acid
  • (2S)-alpha-2-Amino-4-methylvaleric acid
  • (2S)-alpha-Leucine
  • (S)-(+)-Leucine
  • (S)-Leucine
  • 2-Amino-4-methylvaleric acid
  • L
  • L-Leucin
  • L-Leucine
  • L-Leuzin
  • Leu
  • Leucine
Brand Names
  • Aminosyn 10%
  • Aminosyn 5%
  • Aminosyn 7%
  • Aminosyn 8.5%
  • Bcaa 4% Inj
  • Travasol
  • Vamin 18 Electrolyte-free
Affected Organism Humans and other mammals
Indication Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress.
Pharmacology An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine
Mechanism of action This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
Route of administration intravenous
  • Dietary Supplements
  • Micronutrients
  • Amino Acids, Essential
  • Supplements
CAS number 61-90-5
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682